ClinicalTrials.gg
CompletedNCT02480114Updated Feb 18, 2021Results posted

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

A Phase 3 interventional study of Educational Intervention and Gabapentin in Malignant Head and Neck Neoplasm, Mucositis and Radiation-Induced Disorder, sponsored by Vanderbilt-Ingram Cancer Center. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Vanderbilt-Ingram Cancer Center · Phase 3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center — 5 open to participants now, 5 under way, none of them phase 3. Head and Neck Neoplasms · Vanderbilt-Ingram Cancer Center.

Enrollment
Largest of 16
79 · median 36
Started
2015
the only one that year
Phase 3
Only one
of the 30
Registered
22nd of 30
by date

Among the 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center, this one has the largest enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 3, and was the 22nd registered.

Head and Neck Neoplasms

2,716 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

5 of the 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Head and Neck Neoplasms by Vanderbilt-Ingram Cancer Center, or all of them as a file.
02

Study summary

This randomized phase III trial studies how well gabapentin plus standard of care work compares to standard of care without Gabapentin in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV head and neck cancer that are undergoing primary or subsequent (adjuvant) chemoradiation therapy. Radiation therapy to the head and neck may cause a burn involving the inside of the mouth, throat, and nasal passages, resulting in pain. Gabapentin may help prevent (or minimize) pain associated with radiation-induced mucositis in patients with head and neck cancer.

Read the detailed description

Primary Objectives:

  • To determine whether gabapentin used as a preventive measure during chemoradiation can reduce radiation-induced mucositis associated pain in head and neck cancer patients as measured by: 1) pain scores on the Vanderbilt Head and Neck Symptom Survey (VHNSS version 2.), and 2) analgesic use.

Secondary Objectives:

  • To assess the safety (grade 3 or 4 adverse events) and tolerability of using gabapentin (discontinuation of drug due to side effects - yes or no)
  • To correlate pain severity with frequency and severity of general systemic symptoms.

Exploratory Objectives:

  • To determine whether pain control is associated with weight loss (in pounds) and duration of use of percutaneous endoscopic gastrostomy utilization (in days).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Standard of Care (usual care) - Patients receive consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of chemoradiation treatment to review foundations of oral care and pain management.

ARM II: Standard of Care plus Gabapentin - Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin orally (PO) three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.

After completion of study treatment, patients are followed up monthly for 3 months.

03

Conditions studied

  • Malignant Head and Neck Neoplasm
  • Mucositis
  • Radiation-Induced Disorder
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven cancer of the head and neck cancer
  • Stage 3 or 4
  • Planned primary or chemoradiation therapy
  • Willing and able to provide
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Currently on gabapentin
  • Prior non-tolerance of gabapentin
  • History of seizure disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Active comparator
    Arm I Standard of Care

    Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.

    Other: Educational Intervention · Other: Pain Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Oxycodone/Acetaminophen · Drug: Hydrocodone/Acetaminophen · Drug: Fentanyl · Drug: Ibuprofen · Drug: Magic Mouthwash

  • Experimental
    Arm II Standard of Care Plus Gabapentin

    Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.

    Other: Educational Intervention · Drug: Gabapentin · Other: Pain Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Oxycodone/Acetaminophen · Drug: Hydrocodone/Acetaminophen · Drug: Fentanyl · Drug: Ibuprofen · Drug: Magic Mouthwash

Interventions

  • OtherEducational Intervention

    Undergo oral care and pain management education session

    Also known as: Education for Intervention

  • Given PO

    Also known as: Gralise, Neurontin, 1-(aminomethyl) cyclohexaneacetic Acid, 60142-96-3,

  • OtherPain Therapy

    Receive usual oral health care

    Also known as: Analgesia, Pain Control, Pain Management, Pain

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugOxycodone/Acetaminophen

    Drug page: Oxycodone-acetaminophenStudies of Oxycodone-acetaminophenOxycodone-acetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Analgesia

    Also known as: Percocet

  • DrugHydrocodone/Acetaminophen

    Analgesia

    Also known as: Lortab, Vicodin

  • Transdermal Analgesia

    Also known as: Duragesic

  • NSAID Analgesia

    Also known as: Motrin, Advil

  • DrugMagic Mouthwash

    Oral Solution to treat mucositis

    Also known as: Miracle Mouthwash, First-Mouthwash BLM, First-BXN Mouthwash

06

What researchers measure

Primary outcomes

  1. Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))

    The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.

    Time frame: Up to 3 months post-treatment

Secondary outcomes

  1. Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)

    Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Frequency distributions will summarize the safety outcome.

    Time frame: Up to 3 months post-treatment

  2. Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)

    Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.

    Time frame: Up to 3 months post-treatment

07

Results

Posted Sep 24, 2020

Participant flow

Participants were enrolled at Vanderbilt Medical Center in Nashville, TN from July 2015 to May 2019. 79 participants were recruited and 8 of those withdrew.

Participant flow — Overall Study
MilestoneArm II Standard of Care Plus GabapentinArm I Standard of Care
Started4138
Completed3230
Not completed98
Withdrew: Not completing surveys32
Withdrew: Withdrawal by subject24
Withdrew: Disease progression30
Withdrew: Improper completion of survey11
Withdrew: Not eligible01

Outcome measures

PrimaryChange in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))

The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.

Time frame:
Up to 3 months post-treatment
Reported as:
Median · score on a scale
Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))
score on a scaleArm I Standard of CareArm II Standard of Care Plus Gabapentin
Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))4.26 (3.98 to 5.16)3.68 (2.04 to 3.68)
Statistical analysis
  • Arm I Standard of Care vs Arm II Standard of Care Plus Gabapentin · Proportional Odds Regression · p = 0.004 · Odds ratio (or): 0.549 · 95% CI 0.364 to 0.827
SecondaryNumber of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)

Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Frequency distributions will summarize the safety outcome.

Time frame:
Up to 3 months post-treatment
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)
ParticipantsArm I Standard of CareArm II Standard of Care Plus Gabapentin
Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)00
Statistical analysis
  • Arm I Standard of Care vs Arm II Standard of Care Plus Gabapentin · Fisher Exact · p = 1 · Odds ratio (or): 1
SecondaryFrequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)

Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \< 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.

Time frame:
Up to 3 months post-treatment
Reported as:
Median · score on a scale
Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)
score on a scaleArm I Standard of CareArm II Standard of Care Plus Gabapentin
Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)1.91 (0.73 to 3.56)1.23 (0.45 to 2.79)
Statistical analysis
  • Arm I Standard of Care vs Arm II Standard of Care Plus Gabapentin · Proportional Odds Regression · p = <0.001 · Odds ratio (or): 0.371 · 95% CI 0.244 to 0.597

Adverse events

Collected over Approximately 3 months after completion of treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I Standard of Care0/38 (0%)0/38 (0%)0/38 (0%)
Arm II Standard of Care Plus Gabapentin0/41 (0%)0/41 (0%)2/41 (4.9%)
Most frequent other events
Most frequent other events
EventArm I Standard of CareArm II Standard of Care Plus Gabapentin
FatigueGeneral disorders0/382/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm I Standard of CareArm II Standard of Care Plus GabapentinTotal
<=18 years000
Between 18 and 65 years323466
>=65 years6713
Age, Continuous
Age, Continuous(Years)Arm I Standard of CareArm II Standard of Care Plus GabapentinTotal
Median61.5 (54.75 to 66.25)61 (52 to 66)61 (53 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Arm I Standard of CareArm II Standard of Care Plus GabapentinTotal
Female121426
Male262753
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I Standard of CareArm II Standard of Care Plus GabapentinTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American314
White333972
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)Arm I Standard of CareArm II Standard of Care Plus GabapentinTotal
United States384179
08

Study locations

1 site
  • Vanderbilt University/Ingram Cancer Center
    Nashville, Tennessee 37232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Sep 2019 and a completion of Jan 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2015
First posted
Jun 24, 2015
Start
Jul 2015
Primary completionActual
Sep 2019
CompletionActual
Jan 2020
Results first posted
Sep 24, 2020
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02480114
Responsible party
Derek Smith (Principal Investigator, Vanderbilt-Ingram Cancer Center) — Principal investigator
First posted
Jun 24, 2015
Start date
Jul 2015
Primary completion
Sep 2019
Completion
Jan 2020
Results posted
Sep 24, 2020
Last update
Feb 18, 2021

Study contacts

Derek Smith, DDS,PhD
principal investigator · Vanderbilt University/Ingram Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion